Core Viewpoint - Haixi New Drug announced the results of its new share allocation and will officially list on October 20, following a delay due to the need for additional time to finalize announcements and obtain regulatory approval. This situation raised concerns about a potential failure to list, reminiscent of the previous case with Baide Medical [1]. Group 1: Share Allocation Results - The allocation results show that only 46 participants received 90% of the national allocation, indicating a high concentration of shares among a few investors. The top 25 participants accounted for 99.62% of the national allocation, suggesting a strategy to control and potentially drive up the stock price [2]. - The dark market trading experienced volatility, with rumors of internal conflicts among investors leading to the delay in listing [3]. Group 2: Market Dynamics and Investor Behavior - There were reports of issues with the international placement, including potential duplicate applications and unqualified participants, raising concerns about the integrity of the allocation process [6]. - A significant number of applicants, approximately 316,000, were noted, with speculation that a group of investors, referred to as "monkeys," was involved in the subscription process, impacting the overall subscription rates and profitability for retail investors [7]. Group 3: IPO Distribution Regulations - Following the implementation of new IPO distribution regulations, there has been a noticeable trend where the allocation results show that the tail end of the allocation (甲尾) has a higher success rate compared to the head end (乙头) in many cases, suggesting a shift in strategy for investors [10][11]. - The analysis indicates that for accounts with multiple subscriptions, targeting the tail end may yield better results in terms of cost efficiency and success rates, although this could lead to missing out on larger opportunities [11].
海西新药周一上市交易，10万猴子又来抢货了